Trauma-targeted delivery of tranexamic acid improves hemostasis and survival in rat liver hemorrhage model.

ABSTRACT:

Background

Trauma-associated hemorrhage and coagulopathy remain leading causes of mortality. Such coagulopathy often leads to a hyperfibrinolytic phenotype where hemostatic clots become unstable because of upregulated tissue plasminogen activator (tPA) activity. Tranexamic acid (TXA), a synthetic inhibitor of tPA, has emerged as a promising drug to mitigate fibrinolysis. TXA is US Food and Drug Administration-approved for treating heavy menstrual and postpartum bleeding, and has shown promise in trauma treatment. However, emerging reports also implicate TXA for off-target systemic coagulopathy, thromboembolic complications, and neuropathy.

Objective

We hypothesized that targeted delivery of TXA to traumatic injury site can enable its clot-stabilizing action site-selectively,

SUBMITTER: Girish A 

PROVIDER: S-EPMC10124760 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature